Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,221

Military probing whether cancers linked to nuclear silo work

Nine military officers who had worked decades ago at a nuclear missile base in Montana have been diagnosed with blood cancer and there are “indications” the disease may be linked to their service, according to military briefing slides obtained by The Associated Press. One of the officers has died.

All of the officers, known as missileers, were assigned as many as 25 years ago to Malmstrom Air Force Base, home to a vast field of 150 Minuteman III intercontinental ballistic missile silos. The nine officers were diagnosed with non-Hodgkin lymphoma, according to a January briefing by U.S. Space Force Lt. Col. Daniel Sebeck.

Missileers ride caged elevators deep underground into a small operations bunker encased in a thick wall of concrete and steel. They remain there sometimes for days, ready to turn the launch keys if ordered to by the president.

Anti-aging gene shown to rewind heart age

By ten years.

An anti-aging gene discovered in a population of centenarians has been shown to rewind the heart’s biological age by 10 years. The breakthrough, published in Cardiovascular Research and led by scientists at the University of Bristol and the MultiMedica Group in Italy, offers a potential target for patients with heart failure.

Associated with exceptional longevity, carriers of healthy mutant , like those living in blue zones of the planet, often live to 100 years or more and remain in . These individuals are also less prone to cardiovascular complications. Scientists believe the gene helps to keep their hearts young by protecting them against diseases linked to aging, such as .

In this new study, researchers demonstrate that one of these healthy mutant genes, previously proved particularly frequent in centenarians, can protect cells collected from patients with failure requiring cardiac transplantation.

Alleviating Symptoms: Brain Stimulation Could Help Treat Alzheimer’s Disease

Alzheimer’s disease, which is the most common form of dementia, is challenging to treat. A possible therapy is deep brain stimulation delivered by a pacemaker-like device. A team of researchers from Charité – Universitätsmedizin Berlin discovered that stimulating a specific network in the brains of Alzheimer’s patients can decrease their symptoms. The study, published in the journal Nature Communications.

<em>Nature Communications</em> is a peer-reviewed, open-access, multidisciplinary, scientific journal published by Nature Portfolio. It covers the natural sciences, including physics, biology, chemistry, medicine, and earth sciences. It began publishing in 2010 and has editorial offices in London, Berlin, New York City, and Shanghai.

Taste Cells’ Role in Immune Response May Lead to Treatment of Taste Loss

Summary: A subset of taste cells may play a key role in the body’s immune response to harmful oral microbes. The findings could help taste loss associated with infections, aging, and dysregulation of the oral microbiome caused by chemotherapy.

Source: University of Nebraska Lincoln.

Taste cells are heavily exposed to the microbes in the mouth, but their role in helping the body respond to those microbes has not yet been studied in detail.

DNA sequencing method can detect where and how small molecule drugs interact with their targets

Many life-saving drugs directly interact with DNA to treat diseases such as cancer, but scientists have struggled to detect how and why they work—until now.

In a paper published in the journal Nature Biotechnology, University of Cambridge researchers have outlined a new DNA sequencing method that can detect where and how small molecule drugs interact with the targeted genome.

“Understanding how drugs work in the body is essential to creating better, more ,” said co-first author Dr. Zutao Yu from the Yusuf Hamied Department of Chemistry. “But when a therapeutic drug enters a cancer cell with a genome that has three billion bases, it’s like entering a black box.”

The Next Generation of Humans: Nanobots

Part 1: the future of medicine: nanobots part 2: a new era in mental health: nanobots part 3: the healing power of nanobots part 4: the genetic and data-connected revolution: nanobots part 5: the end of plastic surgery: nanobots part 6: the fertility revolution: nanobots part 7: the job-specific human: nanobots part 8: the end of education as we know it: nanobots part 9: the rise of programmable matter: nanobots part 10: the next generation of humans: nanobots.

Nanotechnology is a rapidly evolving field with the potential to revolutionize medicine in the future. One of the most promising applications of nanotechnology is the use of nanobots in medicine. Nanobots are microscopic robots that can be programmed to perform specialized activities such as disease diagnosis and treatment. They can be used to diagnose and treat a wide range of conditions, including mental illnesses such as depression and anxiety, as well as physical injuries and illnesses.

One of the most interesting potential applications of nanobots in medicine is the treatment of mental illnesses. Mental illnesses are among the most common and devastating diseases of our time. They can be programmed to constantly map the brain and correct faults as they develop. Alzheimer’s disease may theoretically be treated if a person was implanted with nanobots at birth.

Prokaryotic Pangenomes Act as Evolving Ecosystems

Abstract. Understanding adaptation to the local environment is a central tenet and a major focus of evolutionary biology. But this is only part of the adaptionist story. In addition to the external environment, one of the main drivers of genome composition is genetic background. In this perspective, I argue that there is a growing body of evidence that intra-genomic selective pressures play a significant part in the composition of prokaryotic genomes and play a significant role in the origin, maintenance and structuring of prokaryotic pangenomes.

Wearable tech, AI and clinical teams join to change the face of trial monitoring

A multi-disciplinary team of researchers has developed a way to monitor the progression of movement disorders using motion capture technology and AI.

In two ground-breaking studies, published in Nature Medicine, a cross-disciplinary team of AI and clinical researchers have shown that by combining human data gathered from wearable tech with a powerful new medical AI technology they are able to identify clear movement patterns, predict future disease progression and significantly increase the efficiency of clinical trials in two very different rare disorders, Duchenne muscular dystrophy (DMD) and Friedreich’s ataxia (FA).

DMD and FA are rare, degenerative, that affect movement and eventually lead to paralysis. There are currently no cures for either disease, but researchers hope that these results will significantly speed up the search for new treatments.

/* */